These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 2643392

  • 1. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
    Kimura K, Yamada K, Uzuka Y, Masaoka T, Hirano M, Ohno R, Ogawa M.
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):123-30. PubMed ID: 2643392
    [Abstract] [Full Text] [Related]

  • 2. [Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
    Tatsumi N, Yamada K, Ohshima T, Nakamura T, Ohno R, Masaoka T, Kimura I, Kimura K.
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2387-95. PubMed ID: 2260876
    [Abstract] [Full Text] [Related]

  • 3. [Phase I study and early phase II of SM-108 (4-carbamoylimidazolium-5-olate) in lung cancer. SM-108 Study Group].
    Kimura K, Suzuoki Y, Ogawa M, Miyazaki T, Uzuka Y, Sakai Y, Ohno R, Yamada K, Ota K, Yoshida T.
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):113-21. PubMed ID: 2643391
    [Abstract] [Full Text] [Related]

  • 4. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H.
    Cancer; 2003 Jun 01; 97(11):2760-6. PubMed ID: 12767088
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 01; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
    Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B.
    J Clin Oncol; 2011 Jun 20; 29(18):2521-7. PubMed ID: 21576646
    [Abstract] [Full Text] [Related]

  • 10. [A phase II study of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) in patients with acute leukemia and myelodysplastic syndromes. Cooperative Study Group for PL-AC].
    Kimura K.
    Gan To Kagaku Ryoho; 1987 Aug 20; 14(8):2475-81. PubMed ID: 3619459
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.
    Vaena DA, Walker P, Pennington K, Stephens A, Stender MJ, Yiannoutsos CT, Young C, Stoner C, Cripe LD, Hoosier Oncology Group.
    Leuk Res; 2004 Jan 20; 28(1):49-52. PubMed ID: 14630080
    [Abstract] [Full Text] [Related]

  • 12. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M.
    Cytokines Mol Ther; 1995 Mar 20; 1(1):21-8. PubMed ID: 9384660
    [Abstract] [Full Text] [Related]

  • 13. [Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
    Tanaka I, Kobayashi T, Shirakawa S, Ikeda Y, Kobayashi M, Yamagata K, Ohta K, Ohno R, Yamada H, Yamada K.
    Gan To Kagaku Ryoho; 1985 Mar 20; 12(3 Pt 1):493-8. PubMed ID: 3859248
    [Abstract] [Full Text] [Related]

  • 14. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
    Omine M, Yamauchi H.
    Nihon Ketsueki Gakkai Zasshi; 1989 Jul 20; 52(4):800-10. PubMed ID: 2618556
    [Abstract] [Full Text] [Related]

  • 15. Topotecan in the treatment of hematologic malignancies.
    Beran M, Kantarjian H.
    Semin Hematol; 1998 Jul 20; 35(3 Suppl 4):26-31. PubMed ID: 9779879
    [Abstract] [Full Text] [Related]

  • 16. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Jul 20; 82(6):660-3. PubMed ID: 9499664
    [Abstract] [Full Text] [Related]

  • 17. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
    Locatelli F, Pession A, Bonetti F, Maserati E, Prete L, Pedrazzoli P, Zecca M, Prete A, Paolucci P, Cazzola M.
    Leukemia; 1994 May 20; 8(5):844-9. PubMed ID: 8182940
    [Abstract] [Full Text] [Related]

  • 18. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 May 20; 82(5 Suppl):9-12. PubMed ID: 9402747
    [Abstract] [Full Text] [Related]

  • 19. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T, Miyake T, Maekawa I, Kurosawa M, Suzuki S, Noto S, Mori A, Chiba K, Toyoshima T, Hirano T, Morioka M, Tsutsumi Y, Okabe M, Kakinoki Y.
    Int J Hematol; 2000 Jun 20; 71(4):366-71. PubMed ID: 10905057
    [Abstract] [Full Text] [Related]

  • 20. [Ranimustine].
    Masaoka T.
    Gan To Kagaku Ryoho; 1990 Feb 20; 17(2):301-7. PubMed ID: 2405779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.